Daily Dose - Apr 29th, 2024
 
 
Daily Dose | View online
 
April 29, 2024
While much about the future is uncertain, the one thing the pharma industry can count on is that the most digitally mature companies will be best placed for success. These successes provide a roadmap that any business can follow — and promise further opportunities for innovation that are yet to be uncovered.
Xolremdi, a selective CXCR4 antagonist, is the first therapy specifically indicated for patients with WHIM.
The novel mGluR2 PAM medication, licensed by Janssen, failed to delay the time for patients to reach baseline seizure count.
Sponsored
Upholding rigorous quality standards is not only a regulatory imperative but also vital for ensuring the efficacy and safety of pharmaceutical products. And as many pharma manufacturers have discovered, enhanced quality processes can also unlock significant performance improvements.But quality improvements...